Capricor Therapeutics (LTS:0HTB) Other Financing: €0.00 Mil (TTM As of Mar. 2026)


What is Capricor Therapeutics Other Financing?

Capricor Therapeutics LTS:0HTB 37 Other Financing is €0.00 Mil as of Mar. 2026. GuruFocus rates LTS:0HTB with a GF Score™ of 37/100. The stock has 3 warning signs investors should review.

Capricor Therapeutics's Other Financing for the three months ended in Mar. 2026 was €0.00 Mil.

Capricor Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Capricor Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Capricor Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capricor Therapeutics Other Financing Chart

Capricor Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.07 0.06 0.43 10.13

Capricor Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Capricor Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €0.00 Mil mean?
Capricor Therapeutics (LTS:0HTB) has a Other Financing of €0.00 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Capricor Therapeutics and its competitors.
Is Capricor Therapeutics' Other Financing too high?
Capricor Therapeutics' current Other Financing is €0.00 Mil. Overall, Capricor Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' Other Financing compare to COAG and DMRA?
Capricor Therapeutics' Other Financing of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Capricor Therapeutics and its competitors. Capricor Therapeutics's current Other Financing is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Capricor Therapeutics (LTS:0HTB) has a current Other Financing of €0.00 Mil. The current Other Financing is €0.00 Mil. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Capricor Therapeutics (LTS:0HTB), the current Other Financing is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Capricor Therapeutics Business Description

Other Exchanges CAPR:USA4LN2:Germany
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.